Journal of Kerman University of Medical Sciences

Current Issue

By Issue

By Author

Author Index

Keyword Index

About Journal

Aims and Scope

JKMU Ethical Policies

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Metric

Editorial Policies

Data Sharing Policy

Increase in TGF-β and CD4 + CD25 + Regulatory T Cells in Iranian Patients With Type 2 Diabetes :A Case–Control Study

Document Type : Original Article

Authors

1 Department of Immunology & Microbiology, School of Medicine, Arak University of Medical Sciences, Arak, Iran

2 Traditional and Complementary Medicine Research Center (TCMRC), Arak University of Medical Sciences, Arak, Iran

3 Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran

4 Infectious Diseases Research Center (IDRC), Arak University of Medical Sciences, Arak, Iran

Abstract

 
 Background: Patients with type 2 diabetes mellitus (T2DM) often have imbalance in inflammatory cells, increased inflammatory cytokines, and defects in homeostasis. The present study aimed to evaluate the percentage of Treg cells, lymphocytes, T cells, and T helper cells and the expression of the TGF-β cytokine gene in T2DM patients.
Methods : This study was conducted on 50 patients with T2DM and 50 healthy controls according to the inclusion criteria. The percentage of Treg cells, T cells, and T helper cells was determined by flow cytometry. Also, the expression of the CD4, CD25, and FOXP3 markers of Treg cells was examined. The gene expression of TGF-β cytokine was evaluated by real-time polymerase chain reaction (PCR).
Results: The percentage of Treg cells was significantly lower in patients with T2DM than in healthy controls. The number of T helper cells and lymphocytes decreased in T2DM patients as compared to the healthy controls. Based on the results, the percentage of T cells was higher in T2DM patients than in healthy controls. The expression of CD25 and FOXP3 markers in Treg cells significantly decreased in T2DM patients compared to the healthy controls; however, this decrease was not significant for the CD4 marker. Conversely, the expression of the cytokine TGF-β increased in patients with T2DM compared to the healthy controls.
Conclusion: The expression of TGF-β and the percentage of CD4 + CD25 + regulatory T cells were impaired in patients with T2DM.

Highlights

Nazanin Shahnoruzi(google scholar)(pubmed)

Mehdi SalehiNazanin Shahnoruzi(google scholar)(pubmed)

Ali Ganji(google scholar)(pubmed)

Ghasem Mosayebi(google scholar)(pubmed)

Ali Ghazavi(google scholar)(pubmed)

Keywords

Main Subjects

References

  1.  

    1. Lin JD, Hsia TL, Wu CZ, Su CC, Ma WY, Hsieh AT, et al. The first and second phase of insulin secretion in naive Chinese type 2 diabetes mellitus. Metabolism. 2010;59(6):780-6. doi: 10.1016/j.metabol.2009.09.024.
    2. Moradi Y, Baradaran HR, Djalalinia S, Chinekesh A, Khamseh ME, Dastoorpoor M, et al. Complications of type 2 diabetes in Iranian population: an updated systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(3):2300-12. doi: 10.1016/j.dsx.2019.05.018.
    3. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77-82.
    4. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-39. doi: 10.1056/NEJMoa0808431.
    5. Xia C, Rao X, Zhong J. Role of T lymphocytes in type 2 diabetes and diabetes-associated inflammation. J Diabetes Res. 2017;2017:6494795. doi: 10.1155/2017/6494795.
    6. Hall BM. T cells: soldiers and spies--the surveillance and control of effector T cells by regulatory T cells. Clin J Am Soc Nephrol. 2015;10(11):2050-64. doi: 10.2215/cjn.06620714.
    7. Marek-Trzonkowska N, Myśliwec M, Siebert J, Trzonkowski P. Clinical application of regulatory T cells in type 1 diabetes. Pediatr Diabetes. 2013;14(5):322-32. doi: 10.1111/ pedi.12029.
    8. Wang M, Chen F, Wang J, Zeng Z, Yang Q, Shao S. Th17 and Treg lymphocytes in obesity and type 2 diabetic patients. Clin Immunol. 2018;197:77-85. doi: 10.1016/j.clim.2018.09.005.
    9. Zeng C, Shi X, Zhang B, Liu H, Zhang L, Ding W, et al. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med (Berl). 2012;90(2):175-86. doi: 10.1007/s00109-011- 0816-5.
    10. Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, et al. Crucial role of FOXP3 in the development and function of human CD25 + CD4 + regulatory T cells. Int Immunol. 2004;16(11):1643-56. doi: 10.1093/intimm/ dxh165.
    11. Li F, Yang M, Wang L, Williamson I, Tian F, Qin M, et al. Autofluorescence contributes to false-positive intracellular FOXP3 staining in macrophages: a lesson learned from flow cytometry. J Immunol Methods. 2012;386(1-2):101-7. doi: 10.1016/j.jim.2012.08.014.
    12. Alahgholi-Hajibehzad M, Oflazer P, Aysal F, Durmuş H, Gülşen-Parman Y, Marx A, et al. Regulatory function of CD4 + CD25 + + T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1,25-dihydroxyvitamin D3 modulates the suppressor activity. J Neuroimmunol. 2015;281:51-60. doi: 10.1016/j. jneuroim.2015.03.008.
    13. Yang TT, Song SJ, Xue HB, Shi DF, Liu CM, Liu H. Regulatory T cells in the pathogenesis of type 2 diabetes mellitus retinopathy by miR-155. Eur Rev Med Pharmacol Sci. 2015;19(11):2010-5.
    14. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-87. doi: 10.1016/j.cell.2008.05.009.
    15. van Exel E, Gussekloo J, de Craen AJ, Frölich M, Bootsma-van der Wiel A, Westendorp RG. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes. 2002;51(4):1088-92. doi: 10.2337/diabetes.51.4.1088.
    16. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170(6):2081-95. doi: 10.1084/jem.170.6.2081.
    17. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and FOXP3 expression in CD4 + CD25 + regulatory T cells. J Exp Med. 2005;201(7):1061- 7. doi: 10.1084/jem.20042276.
    18. Shevach EM, Davidson TS, Huter EN, Dipaolo RA, Andersson J. Role of TGF-beta in the induction of FOXP3 expression and T regulatory cell function. J Clin Immunol. 2008;28(6):640-6. doi: 10.1007/s10875-008-9240-1.
    19. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7(315):315ra189. doi: 10.1126/scitranslmed.aad4134.
    20. Crispin JC, Martínez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2003;21(3):273-6. doi: 10.1016/s0896-8411(03)00121-5.
    21. Faraji F, Shojapour M, Farahani I, Ganji A, Mosayebi G. Reduced regulatory T lymphocytes in migraine patients. Neurol Res. 2021;43(8):677-82. doi: 10.1080/01616412.2021.1915077.
    22. Ganji A, Farahani I, Khansarinejad B, Ghazavi A, Mosayebi G. Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cells Mol Dis. 2020;83:102437. doi: 10.1016/j.bcmd.2020.102437.
    23. Zhou T, Hu Z, Yang S, Sun L, Yu Z, Wang G. Role of adaptive and innate immunity in type 2 diabetes mellitus. J Diabetes Res. 2018;2018:7457269. doi: 10.1155/2018/7457269.
    24. Aghili B, Amirzargar AA, Rajab A, et al. Altered Suppressor Function of Regulatory T Cells in Type 1 Diabetes. Iran J Immunol. 2015;12(4):240-251.
    25. Shu CJ, Benoist C, Mathis D. The immune system’s involvement in obesity-driven type 2 diabetes. Semin Immunol. 2012;24(6):436-42. doi: 10.1016/j.smim.2012.12.001.
    26. Yun JM, Jialal I, Devaraj S. Effects of epigallocatechin gallate on regulatory T cell number and function in obese v. lean volunteers. Br J Nutr. 2010;103(12):1771-7. doi: 10.1017/ s000711451000005x.
    27. Zeng L, Lu H, Deng H, Mu P, Li X, Wang M. Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment. Diabetes Technol Ther. 2012;14(1):35-42. doi: 10.1089/dia.2011.0123.
    28. Qiao YC, Shen J, He L, Hong XZ, Tian F, Pan YH, et al. Changes of regulatory T cells and of proinflammatory and immunosuppressive cytokines in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Diabetes Res. 2016;2016:3694957. doi: 10.1155/2016/3694957.
    29. Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K, et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ ob mice. Proc Natl Acad Sci U S A. 2010;107(21):9765-70. doi: 10.1073/pnas.0908771107.
    30. Liu Y, Zheng WK, Gao WS, Shen Y, Ding WY. Function of TGF-beta and p38 MAKP signaling pathway in osteoblast differentiation from rat adipose-derived stem cells. Eur Rev Med Pharmacol Sci. 2013;17(12):1611-9.
    31. Yuan N, Zhang HF, Wei Q, Wang P, Guo WY. Expression of CD4+CD25+Foxp3+ Regulatory T Cells, Interleukin 10 and Transforming Growth Factor β in Newly Diagnosed Type 2 Diabetic Patients. Exp Clin Endocrinol Diabetes. 2018;126(2):96-101. doi:10.1055/s-0043-113454.
    32. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2010;28:445-89. doi: 10.1146/annurev-immunol-030409-101212.
    33. Abbasi F, Amiri P, Sayahpour FA, Pirmoradi S, Abolhalaj M, Larijani B, et al. TGF-β and IL-23 gene expression in unstimulated PBMCs of patients with diabetes. Endocrine. 2012;41(3):430-4. doi: 10.1007/s12020-011-9578-7.
    34. McLaughlin T, Liu LF, Lamendola C, Shen L, Morton J, Rivas H, et al. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscler Thromb Vasc Biol. 2014;34(12):2637-43. doi: 10.1161/atvbaha.114.304636.
    35. Kraakman MJ, Murphy AJ, Jandeleit-Dahm K, Kammoun HL. Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function? Front Immunol. 2014;5:470. doi: 10.3389/ fimmu.2014.00470.
    36. Yang L, Ye Q, Yuan XL, Han J, Zhou J, Fan L. Detection of CD4 + CD25 + FOXP3 + regulatory T cells and expression of glucocorticoid-induced tumor necrosis factor receptor (GITR) in peripheral blood of rheumatoid arthritis patients by flow cytometry. Chin J Clin Lab Sci. 2008;4.
    37. Li Z, Li D, Tsun A, Li B. FOXP3 + regulatory T cells and their functional regulation. Cell Mol Immunol. 2015;12(5):558-65. doi: 10.1038/cmi.2015.10.
    38. Zhang C, Xiao C, Wang P, Xu W, Zhang A, Li Q, et al. The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Hum Immunol. 2014;75(4):289-96. doi: 10.1016/j.humimm.2014.02.007.

     

     

Journal of Kerman University of Medical Sciences
Volume 31, Issue 1
March and April 2024
Pages 40-45
Files
Share
How to cite
Statistics